查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1417560

週邊神經病變市場報告：2030 年趨勢、預測與競爭分析

Peripheral Neuropathy Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 - page report | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

週邊神經病變的趨勢和預測

預計 2024 年至 2030 年，全球週邊神經病變市場將以 7.0% 的複合年成長率成長。該市場的主要驅動力是老年人和肥胖人口的快速成長以及糖尿病的增加。全球週邊神經病變市場的未來充滿希望，醫院/診所和門診中心市場充滿機會。

週邊神經病變市場洞察

Lucintel 預測，在預測期內，藥物治療將繼續佔據較大佔有率，因為它更有效且更容易使用。

在這個市場中，醫院和診所將繼續成為較大的細分市場，因為這些設施提供多種治療方法以及專家的存在。

由於糖尿病盛行率高且醫療基礎設施發達，北美在預測期內仍是最大的地區。

常問問題

Q1.市場成長預測如何？

A1. 預計 2024 年至 2030 年，全球週邊神經病變市場將以 7.0% 的複合年成長率成長。

Q2.影響市場成長的主要促進因素有哪些？

A2. 這個市場的主要促進因素是老年人和肥胖人口的快速增加以及糖尿病的增加。

Q3.市場的主要細分市場有哪些？

A3. 週邊神經病變市場的未來性充滿希望，醫院/診所和門診中心市場充滿機會。

Q4.市場上主要企業有哪些？

A4.週邊神經病變的主要企業如下。

  • Abbott
  • Bristol Myers Squibb
  • Novartis
  • Eli Lilly
  • Pfizer

Q5.未來最大的細分市場是什麼？

A5.Lucintel 預計藥物治療在預測期內仍將佔據較大佔有率，因為它更有效且更易於使用。

Q6. 未來五年預計哪個地區將成為最大的市場？

A6. 由於糖尿病盛行率高且醫療基礎設施發達，北美在預測期內仍將是最大的地區。

Q7. 可以客製化報告嗎？

A7. 是的，Lucintel 提供 10% 的客製化服務，無需額外費用。

目錄

第1章執行摘要

第2章全球週邊神經病變市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球週邊神經病變市場趨勢（2018-2023）與預測（2024-2030）
  • 按類型分類的全球週邊神經病變市場
    • 糖尿病週邊神經病變
    • 化療引起的周邊神經病變
    • 特發性週邊神經病變
    • HIV/愛滋病相關的周邊神經病變
  • 按治療分類的全球週邊神經病變市場
    • 藥物治療
    • 非藥物治療
    • 其他
  • 按最終用途分類的全球週邊神經病變市場
    • 醫院和診所
    • 門診中心
    • 其他

第4章 2018-2030年區域市場趨勢及預測分析

  • 全球週邊神經病變市場（按地區）
  • 北美週邊神經病變市場
  • 歐洲週邊神經病變市場
  • 亞太週邊神經病變市場
  • 其他地區週邊神經病變市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 按類型分類的全球週邊神經病變市場成長機會
    • 全球週邊神經病變市場的治療成長機會
    • 全球週邊神經病變市場成長機會（依最終用途）
    • 全球週邊神經病變市場按地區成長機會
  • 全球週邊神經病變市場的新興趨勢
  • 戰略分析
    • 新產品開發
    • 全球週邊神經病變市場的產能擴張
    • 全球週邊神經病變市場的合併、收購和合資企業
    • 認證和許可

第7章主要企業概況

  • Abbott
  • Bristol Myers Squibb
  • Novartis
  • Eli Lilly
  • Pfizer
簡介目錄

Peripheral Neuropathy Trends and Forecast

The future of the global peripheral neuropathy market looks promising with opportunities in the hospital and clinic and ambulatory center markets. The global peripheral neuropathy market is expected to grow with a CAGR of 7.0% from 2024 to 2030. The major drivers for this market are surge in geriatric and obese population and increasing occurence of diabetes.

A more than 150-page report is developed to help in your business decisions.

Peripheral Neuropathy by Segment

The study includes a forecast for the global peripheral neuropathy by type, treatment, end use, and region.

Peripheral Neuropathy Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Diabetic Peripheral Neuropathy
  • Chemotherapy-Induced Peripheral Neuropathy
  • Idiopathic Peripheral Neuropathy
  • HIV/AIDS Associated Peripheral Neuropathy

Peripheral Neuropathy Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

  • Pharmacological Therapies
  • Non-Pharmacological Therapies
  • Others

Peripheral Neuropathy Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals and Clinics
  • Ambulatory Centers
  • Others

Peripheral Neuropathy Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Peripheral Neuropathy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies peripheral neuropathy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the peripheral neuropathy companies profiled in this report include-

  • Abbott
  • Bristol Myers Squibb
  • Novartis
  • Eli Lilly
  • Pfizer

Peripheral Neuropathy Market Insights

Lucintel forecasts that pharmacological therapy will remain the larger segment over the forecast period as it is more effective and easy to use.

Within this market, hospital and clinic will remain the larger segment due to availability of different treatment methods along with presence of expertise in these facilities.

North America will remain the largest region over the forecast period due to high prevalence of diabetes patients and presence of healthcare infrastructure in the region.

Features of the Global Peripheral Neuropathy Market

Market Size Estimates: Peripheral neuropathy market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Peripheral neuropathy market size by type, treatment, end use, and region in terms of value ($B).

Regional Analysis: Peripheral neuropathy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, treatment, end uses, and regions for the peripheral neuropathy market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the peripheral neuropathy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for peripheral neuropathy market?

Answer: The global peripheral neuropathy market is expected to grow with a CAGR of 7.0% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the peripheral neuropathy market?

Answer: The major drivers for this market are surge in geriatric and obese population and increasing occurence of diabetes.

Q3. What are the major segments for peripheral neuropathy market?

Answer: The future of the peripheral neuropathy market looks promising with opportunities in the hospital and clinic and ambulatory center markets.

Q4. Who are the key peripheral neuropathy market companies?

Answer: Some of the key peripheral neuropathy companies are as follows.

  • Abbott
  • Bristol Myers Squibb
  • Novartis
  • Eli Lilly
  • Pfizer

Q5. Which peripheral neuropathy market segment will be the largest in future?

Answer: Lucintel forecasts that pharmacological therapy will remain the larger segment over the forecast period as it is more effective and easy to use.

Q6. In peripheral neuropathy market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to high prevalence of diabetes patients and presence of healthcare infrastructure in the region.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the peripheral neuropathy market by type (diabetic peripheral neuropathy, chemotherapy-induced peripheral neuropathy, idiopathic peripheral neuropathy, and HIV/AIDS associated peripheral neuropathy), treatment (pharmacological therapies, non-pharmacological therapies, and others), end use (hospitals and clinics, ambulatory centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Peripheral Neuropathy Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Peripheral Neuropathy Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Peripheral Neuropathy Market by Type
    • 3.3.1: Diabetic Peripheral Neuropathy
    • 3.3.2: Chemotherapy-induced Peripheral Neuropathy
    • 3.3.3: Idiopathic Peripheral Neuropathy
    • 3.3.4: HIV/AIDS Associated Peripheral Neuropathy
  • 3.4: Global Peripheral Neuropathy Market by Treatment
    • 3.4.1: Pharmacological Therapies
    • 3.4.2: Non-Pharmacological Therapies
    • 3.4.3: Others
  • 3.5: Global Peripheral Neuropathy Market by End Use
    • 3.5.1: Hospitals and Clinics
    • 3.5.2: Ambulatory Centers
    • 3.5.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Peripheral Neuropathy Market by Region
  • 4.2: North American Peripheral Neuropathy Market
    • 4.2.1: North American Peripheral Neuropathy Market by Treatment: Pharmacological Therapies, Non-Pharmacological Therapies, and Others
    • 4.2.2: North American Peripheral Neuropathy Market by End Use: Hospitals and Clinics, Ambulatory Centers, and Others
  • 4.3: European Peripheral Neuropathy Market
    • 4.3.1: European Peripheral Neuropathy Market by Treatment: Pharmacological Therapies, Non-Pharmacological Therapies, and Others
    • 4.3.2: European Peripheral Neuropathy Market by End Use: Hospitals and Clinics, Ambulatory Centers, and Others
  • 4.4: APAC Peripheral Neuropathy Market
    • 4.4.1: APAC Peripheral Neuropathy Market by Treatment: Pharmacological Therapies, Non-Pharmacological Therapies, and Others
    • 4.4.2: APAC Peripheral Neuropathy Market by End Use: Hospitals and Clinics, Ambulatory Centers, and Others
  • 4.5: ROW Peripheral Neuropathy Market
    • 4.5.1: ROW Peripheral Neuropathy Market by Treatment: Pharmacological Therapies, Non-Pharmacological Therapies, and Others
    • 4.5.2: ROW Peripheral Neuropathy Market by End Use: Hospitals and Clinics, Ambulatory Centers, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Peripheral Neuropathy Market by Type
    • 6.1.2: Growth Opportunities for the Global Peripheral Neuropathy Market by Treatment
    • 6.1.3: Growth Opportunities for the Global Peripheral Neuropathy Market by End Use
    • 6.1.4: Growth Opportunities for the Global Peripheral Neuropathy Market by Region
  • 6.2: Emerging Trends in the Global Peripheral Neuropathy Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Peripheral Neuropathy Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Peripheral Neuropathy Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Abbott
  • 7.2: Bristol Myers Squibb
  • 7.3: Novartis
  • 7.4: Eli Lilly
  • 7.5: Pfizer